Ronald C Chen1, R Bryan Rumble1, D Andrew Loblaw1, Antonio Finelli1, Behfar Ehdaie1, Matthew R Cooperberg1, Scott C Morgan1, Scott Tyldesley1, John J Haluschak1, Winston Tan1, Stewart Justman1, Suneil Jain2. 1. Ronald C. Chen, University of North Carolina, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; D. Andrew Loblaw, Sunnybrook Health Sciences Centre; Antonio Finelli, Princess Margaret Hospital, Toronto; Scott C. Morgan, University of Ottawa, Ottawa, Ontario; Scott Tyldesley, The British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada; Behfar Ehdaie, Memorial Sloan Kettering Cancer Center, New York, NY; Matthew R. Cooperberg, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; John J. Haluschak, Dayton Physicians Network, Dayton, OH; Winston Tan, Mayo Clinic Florida, Jacksonville, FL; Stewart Justman, University of Montana, Missoula, MT; and Suneil Jain, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. 2. Ronald C. Chen, University of North Carolina, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; D. Andrew Loblaw, Sunnybrook Health Sciences Centre; Antonio Finelli, Princess Margaret Hospital, Toronto; Scott C. Morgan, University of Ottawa, Ottawa, Ontario; Scott Tyldesley, The British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada; Behfar Ehdaie, Memorial Sloan Kettering Cancer Center, New York, NY; Matthew R. Cooperberg, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; John J. Haluschak, Dayton Physicians Network, Dayton, OH; Winston Tan, Mayo Clinic Florida, Jacksonville, FL; Stewart Justman, University of Montana, Missoula, MT; and Suneil Jain, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. guidelines@asco.org.
Abstract
PURPOSE: To endorse Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. METHODS: The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. RESULTS: The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel. RECOMMENDATIONS: For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.
PURPOSE: To endorse Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. METHODS: The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. RESULTS: The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel. RECOMMENDATIONS: For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.
Authors: John R Srigley; Brett Delahunt; Lars Egevad; Hemamali Samaratunga; John Yaxley; Andrew J Evans Journal: Can Urol Assoc J Date: 2016 Sep-Oct Impact factor: 1.862
Authors: Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben Journal: Cochrane Database Syst Rev Date: 2020-06-04
Authors: Lucas W Dean; Melissa Assel; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Behfar Ehdaie; Samson W Fine Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Stacy Loeb; Nataliya K Byrne; Binhuan Wang; Danil V Makarov; Daniel Becker; David R Wise; Herbert Lepor; Dawn Walter Journal: Eur Urol Date: 2020-02-22 Impact factor: 20.096